A950200 Stock Overview
Engages in the provision of multi-omics solutions for clinical and research purposes.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Psomagen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,805.00 |
| 52 Week High | ₩6,700.00 |
| 52 Week Low | ₩3,880.00 |
| Beta | 0.092 |
| 11 Month Change | 2.02% |
| 3 Month Change | 1.69% |
| 1 Year Change | -20.05% |
| 33 Year Change | -58.40% |
| 5 Year Change | n/a |
| Change since IPO | -68.18% |
Recent News & Updates
Shareholder Returns
| A950200 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -19.1% | 0.3% | -0.8% |
| 1Y | -20.0% | 35.7% | 2.1% |
Return vs Industry: A950200 underperformed the KR Biotechs industry which returned 35.7% over the past year.
Return vs Market: A950200 underperformed the KR Market which returned 2.1% over the past year.
Price Volatility
| A950200 volatility | |
|---|---|
| A950200 Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A950200's share price has been volatile over the past 3 months.
Volatility Over Time: A950200's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 97 | n/a | www.psomagen.com |
Psomagen, Inc. engages in the provision of multi-omics solutions for clinical and research purposes. The company provides genomics, a study of gene sequence and expression; epigenomics, a study of epigenetic changes, such as chromatin assembly, histone modification, and DNA-protein interaction in a cell; metagenomics, a study of genetic material from microorganisms in heterogeneous samples; transcriptomics, a study of RNA and its expression through sequencing, offered to analyze the impact of gene expression on the biology of an organism; and proteomics, a study of all the expressed proteins in an organism (proteome). It also offers Bioinformatics, a software tool and pipeline that helps scientists in analyzing data, as well as provides clinical testing solutions.
Psomagen, Inc. Fundamentals Summary
| A950200 fundamental statistics | |
|---|---|
| Market cap | ₩92.43b |
| Earnings (TTM) | -₩6.02b |
| Revenue (TTM) | ₩33.31b |
2.8x
P/S Ratio-15.4x
P/E RatioIs A950200 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A950200 income statement (TTM) | |
|---|---|
| Revenue | ₩33.31b |
| Cost of Revenue | ₩26.35b |
| Gross Profit | ₩6.96b |
| Other Expenses | ₩12.98b |
| Earnings | -₩6.02b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -312.80 |
| Gross Margin | 20.91% |
| Net Profit Margin | -18.06% |
| Debt/Equity Ratio | 0.3% |
How did A950200 perform over the long term?
See historical performance and comparison